Table 3.
Current ongoing clinical trials for the combination of Aβ and/or tau immunotherapy (Clinicaltrials.gov, as of 1 October 2022).
| Agents | Immunization | Target | Phase | Study Population | Clinical Trial # | Status | Sponsor(s) |
|---|---|---|---|---|---|---|---|
| Gantenerumab & Solanezumab | Passive | Aβ (2–11, 18–27, and 16–26) | Phase III | With risk for or with early onset AD caused by genetic mutation | NCT01760005 | Recruiting | WUSM; Eli Lilly, Roche; AA; NIA; Avid Radiopharmaceuticals, AMP |
| Donanemab & Aducanumab | Passive | p3–7 and Aβ (3–7) | Phase III | Early symptomatic AD | NCT05108922 | Active, not recruiting | Eli Lilly |
| Lecanemab & E2814 | Passive | Aβ protofibrils (1–16) and Tau (273–291, 296–314) | Phase III | Early onset AD caused by genetic mutation | NCT05269394 | Recruiting | WUSM, NIA, AMP, Eisai, AA |
AA, Alzheimer’s Association; AMP, Accelerating Medicines Partnership; NIA, National Institute on Aging; WUSM, Washington University School of Medicine.